Patents Assigned to The Buck Institute for Age Research
-
Patent number: 9885704Abstract: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.Type: GrantFiled: July 15, 2015Date of Patent: February 6, 2018Assignee: The Buck Institute for Age ResearchInventors: Kayvan R. Niazi, Shahrooz Rabizadeh, Dale E. Bredesen
-
Patent number: 8895031Abstract: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.Type: GrantFiled: April 29, 2010Date of Patent: November 25, 2014Assignee: The Buck Institute for Age ResearchInventors: Kayvan R. Niazi, Shahrooz Rabizadeh, Dale E. Bredesen
-
Patent number: 8329653Abstract: The invention provides methods and compositions for reducing or inhibiting net beta-amyloid peptide production and/or amyloid plaque formation. The methods and compositions involve administering a netrin-1 polypeptide or netrin-1 therapeutic to a subject in need thereof.Type: GrantFiled: April 16, 2007Date of Patent: December 11, 2012Assignees: Buck Institute for Age Research, Centre National de la Recherche ScientifiqueInventors: Patrick Mehlen, Dale E. Bredesen, Filipe Calheiros-Lourenco, Veronica Galvan
-
SCREENING SYSTEM FOR MODULATORS OF HER2 MEDIATED TRANSCRIPTION AND HER2 MODULATORS IDENTIFED THEREBY
Publication number: 20120264159Abstract: This invention pertains to the development of a screening system to identify (screen for) HER2 promoter silencing agents. Such agents are expected to be of therapeutic value in the treatment of cancers characterized by HER2 amplification/upregulation. In addition, this invention pertains to the discovery that histone deacetylase (HDAC) inhibitors like sodium butyrate and trichostatin A (TSA), in a time and dose dependent fashion can silence genomically integrated and/or amplified/overexpressing promoters, such as that driving the HER2/ErbB2/neu oncogene, resulting in inhibition of gene products including transcripts and protein, and subsequent production of tumor/cell growth inhibition, apoptosis and/or differentiation. In another embodiment, this invention provides novel SNPs associated with the coding region of the ERbB2 proto-oncogene. The SNPs are indicators for altered risk, for developing ErbB2-positive cancer in a mammal.Type: ApplicationFiled: March 17, 2010Publication date: October 18, 2012Applicant: BUCK INSTITUTE FOR AGE RESEARCHInventor: Christopher C. Benz -
Publication number: 20120071468Abstract: The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam. The methods also are useful for prophylactic and therapeutic treatment of amyloidogenic diseases, including Alzheimer's disease.Type: ApplicationFiled: August 19, 2011Publication date: March 22, 2012Applicant: Buck Institute for Age ResearchInventors: Varghese John, Dale E. Bredesen
-
Publication number: 20110135689Abstract: The present invention is directed to compounds and methods for treating a mammal exposed to Francisella tularensis.Type: ApplicationFiled: November 29, 2010Publication date: June 9, 2011Applicants: University of Iowa Research Foundation, Buck Institute for Age ResearchInventors: Michael A. Apicella, Molly K. McLendon, Bradford W. Gibson, Deborah M.B. Post
-
Publication number: 20100099609Abstract: This invention provides methods of reducing levels of amyloid beta (A?) protein and/or netrin-1 in a mammal. In certain embodiments the methods involve administering to the mammal a fragment of an amyloid precursor protein, or a mutant amyloid precursor protein, in an amount sufficient to decrease circulating levels of free A? protein in said mammal, wherein said fragment is a fragment of the extracellular domain of APP or a mutant thereof that binds amyloid beta protein and/or netrin-1.Type: ApplicationFiled: July 28, 2009Publication date: April 22, 2010Applicant: BUCK INSTITUTE FOR AGE RESEARCHInventors: VARGHESE JOHN, CLARE PETERS-LIBEU, DALE E. BREDESEN
-
Patent number: 7605128Abstract: This invention pertains to the identification of neurogenerative and/or neurotrophic factors that can induce migration of stem cells to neural tissue and/or induce proliferation and/or differentiation of such cells into neurons. Such agents include, but are not limited to stem cell factor (SCF), heparin binding EGF (HB-EGF), and VEGF.Type: GrantFiled: February 14, 2003Date of Patent: October 20, 2009Assignee: Buck Institute for Age ResearchInventors: David C. Greenberg, Kunlin Jin, Xiao Ou Mao, Lin Xie, Yunjuan Sun, Jocelyn Childs
-
Publication number: 20090181881Abstract: The invention provides a method for reducing or inhibiting net beta-amyloid peptide production and amyloid plaque formation associated with Alzheimer's Disease by administering to a subject an amount of a netrin-1 polypeptide, wherein the netrin-1 polypeptide comprises an amino acid sequence that a) binds to a naturally occurring APP protein and b) inhibits A? peptide production. A netrin-1 polypeptide has an amino acid sequence sufficient for specific binding of the netrin-1 polypeptide to the APP protein. A netrin-1 polypeptide can mimic netrin-1-mediated signal transduction by altering the localization, protein-protein binding and/or enzymatic activity of an intracellular protein involved in an APP signal pathway.Type: ApplicationFiled: April 16, 2007Publication date: July 16, 2009Applicant: Buck Institute for Age ResearchInventors: Patrick Mehlen, Dale E. Bredesen, Filipe Calheiros-Lourenco, Veronica Galvan
-
Publication number: 20040101874Abstract: Mitochondrial targets for drug screening assays and for therapeutic intervention in the treatment of diseases associated with altered mitochondrial function are provided. Complete amino acid sequences [SEQ ID NOS:1-3025] of polypeptides that comprise the human heart mitochondrial proteome are provided, using fractionated proteins derived from highly purified mitochondrial preparations, to identify previously unrecognized mitochondrial molecular components.Type: ApplicationFiled: April 4, 2003Publication date: May 27, 2004Applicants: MitoKor Inc., The Buck Institute for Age ResearchInventors: Soumitra S. Ghosh, Eoin D. Fahy, Bing Zhang, Bradford W. Gibson, Steven W. Taylor, Gary M. Glenn, Dale E. Warnock, Sara P. Gaucher